Abstract: This invention provides a polymer-bonded CA4 pharmaceutical compound and a preparation method therefor. The polymer-bonded CA4 drug provided in this invention has a structure represented by formula (I). With respect to the bonded pharmaceutical compound provided by this invention, CA4 is grafted onto a specific polymer carrier, so that the resultant bonded drug may be enriched in tumor vessels and the active drug is slowly released. Therefore, an efficacy of destroying tumor vessels is exerted at a tumor site for a long period, an excellent tumor inhibition effect is achieved, and the problem of poor therapeutic effects due to short action time of CA4P is effectively solved, and thus it has a broad prospect of development in the field of tumor treatment. Additionally, the preparation method provided in this invention is simple and has wide sources of raw materials, and it is possible to achieve scale production and industrialization.

Abstract: A CDDP complex is formed by complexation of CDDP and a polymer having a structure of Formula (I). The CDDP complex has good biocompatibility and is degradable. A side chain of the polymer is grafted with polyethylene glycol, which gives the CDDP complex good dissolvability. When dissolved in an aqueous medium, the CDDP is protected by a hydrophilic polyethylene glycol chain segment and a hydrophobic amino acid chain segment, which can effectively avoid a sudden release of the CDDP due to the influence of the blood circulation system after intravenous injection, thus improving the stability of the CDDP complex. A carboxyl group contained in the CDDP complex has pH value sensitivity and tends to be deprotonated in a low pH environment, which is advantageous for promoting the release of a drug, and improving the efficiency of the drug.

Abstract: A CDDP complex is formed by complexation of CDDP and a polymer having a structure of Formula (I). The CDDP complex has good biocompatibility and is degradable. A side chain of the polymer is grafted with polyethylene glycol, which gives the CDDP complex good dissolvability. When dissolved in an aqueous medium, the CDDP is protected by a hydrophilic polyethylene glycol chain segment and a hydrophobic amino acid chain segment, which can effectively avoid a sudden release of the CDDP due to the influence of the blood circulation system after intravenous injection, thus improving the stability of the CDDP complex. A carboxyl group contained in the CDDP complex has pH value sensitivity and tends to be deprotonated in a low pH environment, which is advantageous for promoting the release of a drug, and improving the efficiency of the drug.